PHILADELPHIA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that members of company management or principal investigators will participate in upcoming industry, medical and investor conferences.
Jeffrey D. Marrazzo, chief executive officer, will participate in panel discussions at the following conferences:
- Personalized Medicine Coalition’s 13th Annual Personalized Medicine Conference on “The Designer Genome: Exploring the Implications of Gene Editing and Gene Therapy for the Future of Medicine and Humanity” on Wednesday, Nov. 15, at 1:00 PM ET at the Joseph B. Martin Conference Center at Harvard Medical School in Boston
- Forbes Healthcare Summit on “Gene Therapy Comes of Age” on Thursday, Nov. 30, at 2:45 PM ET at the Jazz at Lincoln Center in New York
The company plans to participate in the following industry or medical conferences:
World Federation of Hemophilia (WFH) Global Forum, at the Marriott Château Champlain in Montreal
- John Furey, chief operating officer, will participate in a panel discussion on “How Will We Afford New Treatments?” on Thursday, Nov. 9. For the time of the panel discussion, please click here.
- Marcus E. Carr, M.D., head of clinical development, will present previously disclosed data in an “Overview of Spark Adeno-Associated Virus Mediated Gene Transfer Platforms for Investigational Hemophilia A and B Programs” on Friday, Nov. 10, at 8:30 AM ET
American Academy of Ophthalmology (AAO), at the Ernest N. Morial Convention Center in New Orleans
- Albert M. Maguire, M.D., a principal investigator for the Phase 3 clinical trial of LUXTURNATM (voretigene neparvovec), professor of ophthalmology at the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine and attending physician in the Division of Pediatric Ophthalmology at Children's Hospital of Philadelphia, will present at AAO Retina Subspecialty Day on “Three-Year Update for Phase 3 Voretigene Neparvovec Study in Biallelic RPE65-Mediated Inherited Retinal Disease” on Friday, Nov. 10, at 4:01PM CT
- Stephen R. Russell, M.D., a principal investigator for the Phase 3 clinical trial of LUXTURNA, Schrage Professor of Ophthalmology at the Stephen A. Wynn Institute for Vision Research at the University of Iowa, will present at AAO 2017 on “Phase 3 Trial Update of Voretigene Neparvovec in Biallelic RPE65-Mediated Inherited Retinal Disease” on Tuesday, Nov. 14, at 10:15 AM CT
Additionally, company management will present at the following investor conferences:
- Credit Suisse Healthcare Conference on Wednesday, Nov. 8, at 10:25 AM MT, at The Phoenician in Scottsdale, Ariz.
- Stifel Healthcare Conference on Tuesday, Nov. 14, at 2:00 PM ET, at the Lotte New York Palace in New York
- Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, at 2:00 PM GMT, at the Walford Hilton in London
- Evercore ISI Biopharma Conference on Wednesday, Nov. 29, at 2:45 PM ET, at the Boston Harbor Hotel in Boston
- Barclays Gene Editing/Therapy Summit on Thursday, Nov. 30, at 10:20 AM ET, in New York
About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology directed to the retina and liver, and currently have four programs in clinical trials or under regulatory review, including the first potential gene therapy for a genetic disease in the United States and product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470